The EMA has approved a subcutaneous version of Celltrion infliximab biosimilar, CT-P13 - now called Remsima SC; based on the phase I/III study showing equivalence between SC and IV forms of CT-P13 SC in active rheumatoid arthritis (RA). https://t.co/cJFEk464Wr
Links:
Celltrion Healthcare receives EU marketing authorisation for world’s first subc…
http://bit.ly/34iOlT2
Nov-26-2019
